• 1
    Sissons JG, Bain M, Wills MR. Latency and reactivation of human cytomegalovirus. J Infect 2002; 44:737.
  • 2
    Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999; 180:7027.
  • 3
    Gandhi MK, Wills MR, Sissons JG, Carmichael AJ. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev 2003; 17:25964.
  • 4
    Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:40714.
  • 5
    Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9:54358.
  • 6
    Matthes-Martin S, Aberle SW, Peters C et al. CMV-viraemia during allogenic bone marrow transplantation in paediatric patients: association with survival and graft-versus-host disease. Bone Marrow Transplant 1998; 21(Suppl. 2):S536.
  • 7
    Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113:57119.
  • 8
    Boutolleau D, Deback C, Bressollette-Bodin C et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81:1749.
  • 9
    Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99:115964.
  • 10
    Kapp M, Tan SM, Einsele H, Grigoleit G. Adoptive immunotherapy of HCMV infection. Cytotherapy 2007; 9:699711.
  • 11
    Quinnan GV Jr, Kirmani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307:713.
  • 12
    Giest S, Grace S, Senegaglia AC et al. Cytomegalovirus-specific CD8+ T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies. Br J Haematol 2010; 148:31122.
  • 13
    Lacey SF, Martinez J, Gallez-Hawkins G et al. Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J Infect Dis 2005; 191:97784.
  • 14
    Lefranc M-P, Lefranc G. The T cell Receptor FactsBook. San Diego, CA; London: Academic Press, 2001.
  • 15
    Wei S, Charmley P, Robinson MA, Concannon P. The extent of the human germline T-cell receptor V β gene segment repertoire. Immunogenetics 1994; 40:2736.
  • 16
    Fernandes S, Chavan S, Chitnis V, Kohn N, Pahwa S. Simplified fluorescent multiplex PCR method for evaluation of the T-cell receptor V β-chain repertoire. Clin Diagn Lab Immunol 2005; 12:47783.
  • 17
    Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin “superantigens” with human T cells. Proc Natl Acad Sci U S A 1989; 86:89415.
  • 18
    Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008; 36:W5038.
  • 19
    Yousfi Monod M, Giudicelli V, Chaume D, Lefranc MP. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J junctions. Bioinformatics 2004; 20(Suppl. 1):i37985.
  • 20
    Lefranc MP, Giudicelli V, Ginestoux C et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009; 37:D100612.
  • 21
    Wotton D, Ways DK, Parker PJ, Owen MJ. Activity of both Raf and Ras is necessary for activation of transcription of the human T cell receptor beta gene by protein kinase C, Ras plays multiple roles. J Biol Chem 1993; 268:1797582.
  • 22
    Fallen PR, Duarte RF, McGreavey L, Potter M, Ethell M, Prentice HG, Madrigal JA, Travers PJ. Identification of non-naive CD4+ CD45RA+ T cell subsets in adult allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 2003; 32:60916.
  • 23
    Brennan RM, Miles JJ, Silins SL, Bell MJ, Burrows JM, Burrows SR. Predictable αβ T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope. J Virol 2007; 81:726973.
  • 24
    Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169:198492.
  • 25
    Northfield J, Lucas M, Jones H, Young NT, Klenerman P. Does memory improve with age? CD85j (ILT-2/LIR-1) expression on CD8 T cells correlates with ‘memory inflation’ in human cytomegalovirus infection. Immunol Cell Biol 2005; 83:1828.
    Direct Link:
  • 26
    Hadrup SR, Strindhall J, Kollgaard T, Seremet T, Johansson B, Pawelec G, thor Straten P, Wikby A. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 2006; 176:264553.
  • 27
    Folch G, Lefranc MP. The human T cell receptor β variable (TRBV) genes. Exp Clin Immunogenet 2000; 17:4254.
  • 28
    Giudicelli V, Chaume D, Lefranc MP. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 2005; 33:D25661.
  • 29
    Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S. Characterization of human cytomegalovirus peptide-specific CD8+ T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 2002; 99:21323.
  • 30
    Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70:756979.
  • 31
    Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J Virol 1999; 73:2099108.
  • 32
    Kaas Q, Lefranc MP. T cell receptor/peptide/MHC molecular characterization and standardized pMHC contact sites in IMGT/3Dstructure-DB. In Silico Biol 2005; 5:50528.
  • 33
    Wilson RK, Lai E, Concannon P, Barth RK, Hood LE. Structure, organization and polymorphism of murine and human T-cell receptor α and β chain gene families. Immunol Rev 1988; 101:14972.
  • 34
    Rosenberg WM, Moss PA, Bell JI. Variation in human T cell receptor Vβ and Jβ repertoire: analysis using anchor polymerase chain reaction. Eur J Immunol 1992; 22:5419.
  • 35
    Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77:522640.
  • 36
    Gergely L, Czegledy J, Vaczi L. Human antibody response to human cytomegalovirus-specific DNA-binding proteins. Acta Virol 1988; 32:15.
  • 37
    Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:67385.